Aurinia Pharmaceuticals Soars 24% on Positive LUPKYNIS Study Results

Aurinia Pharmaceuticals Inc. (AUPH) reported a 24% increase in total revenue for Q1 2025, reaching $62.5 million compared to $50.3 million in Q1 2024.

Aurinia Pharmaceuticals announced new findings from a post-hoc analysis of the Phase 3 AURORA 1 study, demonstrating that lupus nephritis patients receiving triple immunosuppressive therapy with LUPKYNIS achieved significantly lower proteinuria levels compared to the control group. This suggests that LUPKYNIS-based therapy could lead to better long-term kidney health and reduced cardiovascular risk for patients, reinforcing its critical role in improving health outcomes for lupus nephritis patients.

The findings, presented on May 22, underscore the potential of LUPKYNIS in improving kidney health outcomes for lupus nephritis patients. The company's primary product, LUPKYNIS, is a second-generation calcineurin inhibitor used as an immunosuppressant to treat lupus nephritis, a severe kidney inflammation caused by systemic lupus erythematosus.